Literature DB >> 32453074

Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications.

Vincenzo Russo1, Anna Rago2, Andreina Carbone1, Roberta Bottino1, Ernesto Ammendola2, Nadia Della Cioppa3, Dario Galante4, Paolo Golino1, Gerardo Nigro1.   

Abstract

Coronavirus disease 2019 (COVID-19) outbreak is a public health emergency of international concerns because of a highly pathogenic human coronavirus (HCoV), actually named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite much emerging data about the epidemiological association between cardiovascular diseases and COVID-19, little is still known about atrial fibrillation and its optimal management in this clinical contest. The aim of our review is to describe the pharmacological interactions between cardiovascular drugs more commonly used in atrial fibrillation management and experimental COVID-19 therapies, based on EU and US summaries of product characteristics.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32453074     DOI： 10.1097/FJC.0000000000000854

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN： 0160-2446            Impact factor:   3.105


  15 in total

Review 1.  Arrhythmia in COVID-19.

Authors:  Savalan Babapoor-Farrokhran; Roozbeh Tarighati Rasekhi; Deanna Gill; Shaghayegh Babapoor; Aman Amanullah
Journal:  SN Compr Clin Med       Date:  2020-08-14

2.  Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients.

Authors:  Vincenzo Russo; Andreina Carbone; Filiberto Fausto Mottola; Rosa Mocerino; Raffaele Verde; Emilio Attena; Nicoletta Verde; Pierpaolo Di Micco; Luigi Nunziata; Francesco Santelli; Gerardo Nigro; Sergio Severino
Journal:  Front Pharmacol       Date:  2020-10-08       Impact factor: 5.810

3.  Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study.

Authors:  Vincenzo Russo; Giuseppe Cardillo; Giuseppe Vito Viggiano; Sara Mangiacapra; Antonella Cavalli; Andrea Fontanella; Federica Agrusta; Annamaria Bellizzi; Maria Amitrano; Mariateresa Iannuzzo; Clara Sacco; Corrado Lodigiani; Giampiero Castaldo; Pierpaolo Di Micco
Journal:  Front Med (Lausanne)       Date:  2020-11-27

Review 4.  Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.

Authors:  Carmine Savoia; Massimo Volpe; Reinhold Kreutz
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

5.  Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients.

Authors:  Vincenzo Russo; Roberta Bottino; Antonello D'Andrea; Angelo Silverio; Marco Di Maio; Paolo Golino; Gerardo Nigro; Orazio Valsecchi; Emilio Attena; Mario Enrico Canonico; Gennaro Galasso; Guido Parodi; Fernando Scudiero
Journal:  Cardiovasc Drugs Ther       Date:  2021-05-14       Impact factor: 3.947

Review 6.  Electrocardiography on admission is associated with poor outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.

Authors:  Mochamad Yusuf Alsagaff; Yudi Her Oktaviono; Budi Baktijasa Dharmadjati; Achmad Lefi; Makhyan Jibril Al-Farabi; Parama Gandi; Bagas Adhimurda Marsudi; Yusuf Azmi
Journal:  J Arrhythm       Date:  2021-06-14

7.  Is Atrial Fibrillation a Risk Factor for Worse Outcomes in Severe COVID-19 Patients: A Single Center Retrospective Cohort.

Authors:  Abdulkarim Abdulrahman; Tajammul Hussain; Safraz Nawaz; Shereen AlShaikh; Abdulrahman Almadani; Fawaz Bardooli
Journal:  J Saudi Heart Assoc       Date:  2021-02-17

Review 8.  COVID-19 infection and cardiac arrhythmias.

Authors:  Antonis S Manolis; Antonis A Manolis; Theodora A Manolis; Evdoxia J Apostolopoulos; Despoina Papatheou; Helen Melita
Journal:  Trends Cardiovasc Med       Date:  2020-08-16       Impact factor: 6.677

Review 9.  The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic.

Authors:  Michele Correale; Francesca Croella; Alessandra Leopizzi; Pietro Mazzeo; Lucia Tricarico; Adriana Mallardi; Martino Fortunato; Michele Magnesa; Vincenzo Ceci; Alessandra Puteo; Massimo Iacoviello; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-30       Impact factor: 3.727

Review 10.  Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure.

Authors:  Iman Razeghian-Jahromi; Mohammad Javad Zibaeenezhad; Zhibing Lu; Elyaspour Zahra; Razmkhah Mahboobeh; Vicenzo Lionetti
Journal:  Heart Fail Rev       Date:  2021-03       Impact factor: 4.654
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.